AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36066 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving tasks
Number of subjects: 14
Study 36066 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological parameters and subjective evaluations
Number of subjects: 14
Study 31449573 — intervention group
Group type: COMPARATOR
Intervention: Acellular dermal matrix graft (ADMG) used as a membrane with guided bone regeneration.
Number of subjects: 24
Study 31449573 — intervention group
Group type: EXPERIMENTAL
Intervention: No membrane on buccal overlay graft, ADMG used only to cover the occlusal surface.
Number of subjects: 24
Study 28241247 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 73
Study 28241247 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (1 mg/kg every 6 hours)
Number of subjects: 73
Study 26061092 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EX)
Number of subjects: 103
Study 24218952 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilin Pills (6 g tid) combined with bromocriptine
Number of subjects: 40
Study 24218952 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine alone
Number of subjects: 40
Study 20674417 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg ondansetron
Number of subjects: 100
Study 20674417 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg metoclopramide
Number of subjects: 100
Study 19188677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat breakfast
Number of subjects: 27
Study 19188677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast
Number of subjects: 27
Study 19188677 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 27
Study 16925009 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit approach (Group A)
Number of subjects: 60
Study 16925009 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-visit approach without intracanal dressing (Group B)
Number of subjects: 60
Study 16925009 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-visit approach using calcium hydroxide as an intracanal dressing for one week (Group C)
Number of subjects: 60
Study 15610569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine hydrochloride gel (20 mL of 2% lidocaine gel administered 15 minutes before biopsy)
Number of subjects: 72
Study 15610569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL of ultrasound gel administered under the same conditions)
Number of subjects: 72
Study 15610569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine hydrochloride gel
Number of subjects: 72
Study 15610569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11460891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine monotherapy (2400 mg/day)
Number of subjects: 692
Study 11460891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine adjunctive therapy (600, 1200, 2400 mg/day)
Number of subjects: 692
Study 11460891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine monotherapy
Number of subjects: 692
Study 11460891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine adjunctive therapy
Number of subjects: 692
Study 11460891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine treatment
Number of subjects: 692
Study 10936472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose willow bark extract (240 mg salicin)
Number of subjects: 210
Study 10936472 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose willow bark extract (120 mg salicin)
Number of subjects: 210
Study 10936472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 8725599 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 blocker (famotidine 20mg orally at 9 pm the day before and 2hs before anesthesia)
Number of subjects: 63
Study 8725599 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative drinking (clear fluids until 2hs before anesthesia)
Number of subjects: 63
Study 8725599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no eating or drinking from 9 pm the day before surgery, 500 ml maintenance fluid before anesthesia)
Number of subjects: 63
Study 1483495 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol pretreatment
Number of subjects: 12
Study 1483495 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 20 mg
Number of subjects: 12
Study 1483495 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide with Propranolol
Number of subjects: 12
Study 1483495 — intervention group
Group type: COMPARATOR
Intervention: Furosemide without Propranolol
Number of subjects: 12
Study 3936192 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated procedures
Number of subjects: 0
Study 3936192 — intervention group
Group type: COMPARATOR
Intervention: Non-automated procedures
Number of subjects: 0
Study 30527263 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (3.0 g/d of eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 23
Study 30527263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30527263 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 23
Study 30527263 — intervention group
Group type: COMPARATOR
Intervention: Placebo with resistance training
Number of subjects: 23
Study 26329534 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal mail delivery method
Number of subjects: 7200
Study 26329534 — intervention group
Group type: EXPERIMENTAL
Intervention: Email delivery method
Number of subjects: 7200
Study 26329534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid approach (postal and electronic)
Number of subjects: 7200
Study 24646809 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 36
Study 24646809 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 36
Study 22728482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir plus Entecavir (ADV + ETV) combination therapy
Number of subjects: 91
Study 22728482 — intervention group
Group type: COMPARATOR
Intervention: Adefovir monotherapy
Number of subjects: 91
Study 22728482 — intervention group
Group type: COMPARATOR
Intervention: Adefovir plus Lamivudine (ADV + LAM) therapy
Number of subjects: 91
Study 19941906 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz+Kivexa
Number of subjects: 126
Study 19941906 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/r+Kivexa
Number of subjects: 126
Study 17921037 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT1AR BP in depressed subjects
Number of subjects: 24
Study 17921037 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 16042643 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM (three doses per week)
Number of subjects: 315
Study 16042643 — intervention group
Group type: COMPARATOR
Intervention: Methadone (daily dosing)
Number of subjects: 315
Study 12152003 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celecoxib
Number of subjects: 103
Study 12152003 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 103
Study 12152003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 10406066 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting for acute myocardial infarction
Number of subjects: 0
Study 7762051 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit
Number of subjects: 245
Study 7762051 — intervention group
Group type: COMPARATOR
Intervention: General medical wards
Number of subjects: 245
Study 2280233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (20 ml daily for 6 weeks)
Number of subjects: 0
Study 2280233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cod liver oil for 6 weeks)
Number of subjects: 0
Study 30787899 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 10-min classroom-based exercise break of moderate to vigorous intensity for 9 weeks
Number of subjects: 512
Study 30787899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 512
Study 28866466 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram use after the 2007 NICE guidelines
Number of subjects: 51649
Study 28866466 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram use after the 2011 AAP guidelines
Number of subjects: 51649
Study 28866466 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram use in children 3 to 10 years old
Number of subjects: 51649
Study 28866466 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of vesicoureteral reflux
Number of subjects: 51649
Study 27055960 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil (CO)
Number of subjects: 75
Study 27055960 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO)
Number of subjects: 75
Study 27055960 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (Control)
Number of subjects: 75
Study 27055960 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between RBO and CO
Number of subjects: 75
Study 24526579 — intervention group
Group type: COMPARATOR
Intervention: Continuous Endurance Training (ET)
Number of subjects: 23
Study 24526579 — intervention group
Group type: COMPARATOR
Intervention: Repeated Sprint Training (RST)
Number of subjects: 23
Study 23067364 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial interdisciplinary intervention
Number of subjects: 241
Study 23067364 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 241
Study 20845101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 82
Study 20845101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 82
Study 17765354 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine (DG) - gemcitabine 1100mg/m² on days 1 and 8, docetaxel 75mg/m² on day 8
Number of subjects: 312
Study 17765354 — intervention group
Group type: COMPARATOR
Intervention: Single-agent docetaxel (D) - docetaxel 100mg/m² on day 1
Number of subjects: 312
Study 15949119 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochemical test (OC-Hemodia)
Number of subjects: 7332
Study 15949119 — intervention group
Group type: COMPARATOR
Intervention: Guaiac test (Hemo-Fec)
Number of subjects: 7332
Study 12573788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution B-mode sonography with color flow Doppler
Number of subjects: 90
Study 12573788 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-mode Doppler sonography
Number of subjects: 90
Study 12573788 — intervention group
Group type: COMPARATOR
Intervention: B-mode sonography
Number of subjects: 90
Study 10786204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (4 x 100 mcg daily)
Number of subjects: 44
Study 10786204 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (4 x 40 mcg daily)
Number of subjects: 44
Study 9863162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD) of β‐carboxyethylgermanium sesquioxide (Ge‐132) 1 g · m‐2
Number of subjects: 24
Study 9863162 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose (MD) of β‐carboxyethylgermanium sesquioxide (Ge‐132) 2.5 g · m‐2
Number of subjects: 24
Study 9863162 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) of β‐carboxyethylgermanium sesquioxide (Ge‐132) 4 g · m‐2
Number of subjects: 24
Study 2000792 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanadrel sulfate
Number of subjects: 15
Study 2000792 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 15
Study 6340909 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg extended-release fenfluramine
Number of subjects: 51
Study 6340909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31992327 — intervention group
Group type: EXPERIMENTAL
Intervention: 49Gy/7f (BED10: 83.3Gy)
Number of subjects: 3
Study 31992327 — intervention group
Group type: EXPERIMENTAL
Intervention: 54Gy/6f (BED10: 102.6Gy)
Number of subjects: 3
Study 31992327 — intervention group
Group type: EXPERIMENTAL
Intervention: 55Gy/5f (BED10: 115.5Gy)
Number of subjects: 3
Study 31992327 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study 31743103 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-parent relationship therapy (CPRT) in 10 sessions for 45-60 minutes each
Number of subjects: 60
Study 31743103 — intervention group
Group type: COMPARATOR
Intervention: Routine preschool education
Number of subjects: 60
Study 28440045 — intervention group
Group type: COMPARATOR
Intervention: Lorcaserin 10 mg BID
Number of subjects: 238
Study 28440045 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID + Phentermine 15 mg QD
Number of subjects: 238
Study 28440045 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID + Phentermine 15 mg BID
Number of subjects: 238
Study 26137952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (self-report of current drug therapy for hypertension)
Number of subjects: 6426
Study 26137952 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication with BP ≥140/90 mm Hg (uncontrolled BP)
Number of subjects: 6426
Study 26137952 — intervention group
Group type: COMPARATOR
Intervention: Sodium intake >1,500 mg/day
Number of subjects: 6426
Study 24846935 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam monotherapy
Number of subjects: 0
Study 24846935 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam and macrolide combination therapy
Number of subjects: 0
Study 24846935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone monotherapy
Number of subjects: 0
Study 23004227 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic clips (Clip)
Number of subjects: 48
Study 19885777 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Number of subjects: 10
Study 19885777 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 10
Study 17230616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronase premedication
Number of subjects: 146
Study 17230616 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) premedication
Number of subjects: 146
Study 17230616 — intervention group
Group type: COMPARATOR
Intervention: Gascon
Number of subjects: 146
Study 17230616 — intervention group
Group type: COMPARATOR
Intervention: Gascon water
Number of subjects: 146
Study 17230616 — intervention group
Group type: EXPERIMENTAL
Intervention: CLO test sensitivity and specificity
Number of subjects: 146
Study 15339895 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational epidemiology approaches (observational designs and randomized experimental designs)
Number of subjects: 0
Study 15339895 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive national network of educational epidemiologists
Number of subjects: 0
Study 12549708 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschooler-parent psychotherapy (PPP, n = 23)
Number of subjects: 122
Study 12549708 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational home visitation (PHV, n = 34)
Number of subjects: 122
Study 12549708 — intervention group
Group type: EXPERIMENTAL
Intervention: Community standard (CS, n = 30)
Number of subjects: 122
Study 12549708 — intervention group
Group type: COMPARATOR
Intervention: Nonmaltreating comparison group (NC, n = 35)
Number of subjects: 122
Study 9643060 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-relevant stimuli (auditory and visual)
Number of subjects: 0
Study 9643060 — intervention group
Group type: COMPARATOR
Intervention: Task-irrelevant stimuli
Number of subjects: 0
Study 9643060 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimuli (CSs) in differential conditioning with an aversive unconditioned stimulus (US)
Number of subjects: 0
Study 7862273 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography (CTA) using 60 cc of contrast (medium 2 cc/sec) with 5 mm slices, reconstructed at 3 mm slice thickness (Group 1)
Number of subjects: 20
Study 7862273 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography (CTA) using 90 cc of contrast (medium 3 cc/sec) with 3 mm slices, reconstructed at 1 mm slice thickness (Group 2)
Number of subjects: 20
Study 7862273 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography (control)
Number of subjects: 20
Study 2675587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30, 60 or 90 mg administered once daily
Number of subjects: 0
Study 2675587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31749143 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent screening (ages 22/25/28; Arm 1: 2,073 females)
Number of subjects: 4273
Study 31749143 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent screening (age 28; Arm 2: 2,200 females)
Number of subjects: 4273
Study 31749143 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Arm (females vaccinated at age 18; Arm 3: 1,329 females)
Number of subjects: 4273
Study 30478375 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy descriptor method for predicting synthesizability of high-entropy materials.
Number of subjects: 0
Study 30478375 — intervention group
Group type: EXPERIMENTAL
Intervention: High-entropy homogeneous phases.
Number of subjects: 0
Study 28421240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhenium-188-HEDP combined with docetaxel and prednisone
Number of subjects: 88
Study 28421240 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel and prednisone alone
Number of subjects: 88
Study 26136593 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Polyphenol Concentration in Orange Juice (NPJ)
Number of subjects: 100
Study 26136593 — intervention group
Group type: EXPERIMENTAL
Intervention: High Polyphenol Concentration in Orange Juice (HPJ)
Number of subjects: 100
Study 24016497 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT)
Number of subjects: 2275
Study 24016497 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2275
Study 24016497 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of vessels diseased (VD)
Number of subjects: 2275
Study 20978715 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggrenox
Number of subjects: 0
Study 20978715 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 20978715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18302858 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic component of the new WHO antenatal care model
Number of subjects: 1022
Study 18302858 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing parity
Number of subjects: 1022
Study 16301945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle strengthening
Number of subjects: 0
Study 16301945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Number of subjects: 0
Study 11834646 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of furosemide
Number of subjects: 20
Study 10479834 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA)
Number of subjects: 50
Study 10479834 — intervention group
Group type: COMPARATOR
Intervention: Inhalatory anaesthesia
Number of subjects: 50
Study 7618675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsalis pedis artery measurement
Number of subjects: 0
Study 7618675 — intervention group
Group type: COMPARATOR
Intervention: Radial artery measurement
Number of subjects: 0
Study 2201660 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine
Number of subjects: 0
Study 2201660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6127435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 6127435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 0
Study 30792037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin-neomycin-polymyxin B combination (NNP) for 12 days
Number of subjects: 611
Study 30792037 — intervention group
Group type: COMPARATOR
Intervention: Miconazole for 3 days followed by 9 days of placebo
Number of subjects: 611
Study 30792037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin-neomycin-polymyxin B combination (NNP)
Number of subjects: 611
Study 30792037 — intervention group
Group type: COMPARATOR
Intervention: Miconazole
Number of subjects: 611
Study 28710596 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarette use
Number of subjects: 788
Study 26062622 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG and enteral nutrition
Number of subjects: 726
Study 26062622 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counselling (non-PEG group)
Number of subjects: 726
Study 23617696 — intervention group
Group type: EXPERIMENTAL
Intervention: Conquer Fear Intervention
Number of subjects: 260
Study 23617696 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 260
Study 21542956 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30 mg/kg)
Number of subjects: 50
Study 21542956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 50
Study 19473613 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n = 19)
Number of subjects: 27
Study 19473613 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity aerobic training (n = 8)
Number of subjects: 27
Study 17308528 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA+GA
Number of subjects: 80
Study 17308528 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 80
Study 15179180 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (4 mg x kg)
Number of subjects: 15
Study 15179180 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 15
Study 15179180 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 12562588 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (mean dose=9.5 mg/day at bedtime, SD=0.5)
Number of subjects: 10
Study 12562588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10